Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Evolution of the concept of androgen-sensitive bladder cancer.

Gakis G, Stenzl A, Renninger M.

Scand J Urol. 2013 Jun;47(3):173-8. doi: 10.3109/00365599.2012.756929. Epub 2013 Jan 21. Review.

PMID:
23330817
2.

Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity.

Gakis G, Stenzl A.

World J Urol. 2013 Oct;31(5):1059-64. doi: 10.1007/s00345-013-1037-z. Epub 2013 Feb 9. Review.

PMID:
23397433
3.

Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk.

Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, Ye Y, Malats N, Tang W, Liu L, Garcia-Closas M, Muchmore B, Chatterjee N, Tarway M, Kogevinas M, Porter-Gill P, Baris D, Mumy A, Albanes D, Purdue MP, Hutchinson A, Carrato A, Tardón A, Serra C, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Diver WR, Gapstur SM, Thun MJ, Virtamo J, Chanock SJ, Fraumeni JF Jr, Silverman DT, Wu X, Real FX, Prokunina-Olsson L.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):4974-9. doi: 10.1073/pnas.1202189109. Epub 2012 Mar 13.

4.

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.

Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J.

Nat Genet. 2009 Sep;41(9):991-5. doi: 10.1038/ng.421. Epub 2009 Aug 2. Erratum in: Nat Genet. 2009 Oct;41(10):1156. Guarrera, Simonetta [added]; Polidoro, Silvia [added].

5.

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40.

6.

Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.

Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB.

Genes Chromosomes Cancer. 2000 Jan;27(1):95-103.

PMID:
10564591
7.

Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.

Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, Tindall DJ.

Endocr Relat Cancer. 2009 Mar;16(1):123-37. doi: 10.1677/ERC-08-0124. Epub 2008 Oct 9.

8.

Genetic variation in PSCA is associated with bladder cancer susceptibility in a Korean population.

Lee JH, Song HR, Kim HN, Kweon SS, Yun YW, Choi JS, Jung SI, Kwon DD, Kim SH, Choi YD, Shin MH.

Asian Pac J Cancer Prev. 2014;15(20):8901-4.

9.

Androgen receptor involvement in the progression of prostate cancer.

Suzuki H, Ueda T, Ichikawa T, Ito H.

Endocr Relat Cancer. 2003 Jun;10(2):209-16. Review.

10.

Expression and function of androgen receptor coactivators in prostate cancer.

Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. Epub 2004 Dec 19. Review.

PMID:
15663989
11.

Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF.

Anticancer Res. 2001 Jan-Feb;21(1A):1-10.

PMID:
11299720
12.

The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer.

Avila DM, Zoppi S, McPhaul MJ.

J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):135-42. Review.

PMID:
11384871
13.

Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population.

Wang S, Tang J, Wang M, Yuan L, Zhang Z.

Carcinogenesis. 2010 Apr;31(4):621-4. doi: 10.1093/carcin/bgp323. Epub 2010 Jan 18.

14.

ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.

Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L.

Mol Endocrinol. 2007 Aug;21(8):1835-46. Epub 2007 May 15.

PMID:
17505060
15.
16.

Androgen receptor in prostate cancer.

Heinlein CA, Chang C.

Endocr Rev. 2004 Apr;25(2):276-308. Review.

PMID:
15082523
17.

The androgen receptor in hormone-refractory prostate cancer.

Mao HL, Zhu ZQ, Chen CD.

Asian J Androl. 2009 Jan;11(1):69-73. doi: 10.1038/aja.2008.14. Epub 2008 Dec 1. Review.

18.

Androgens and androgen receptor signaling in prostate tumorigenesis.

Zhou Y, Bolton EC, Jones JO.

J Mol Endocrinol. 2015 Feb;54(1):R15-29. doi: 10.1530/JME-14-0203. Epub 2014 Oct 28. Review.

19.
20.

PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.

Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, Squire JA.

J Pathol. 2009 Aug;218(4):505-13. doi: 10.1002/path.2559.

PMID:
19402094
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk